98%
921
2 minutes
20
Background: An increasing number of reports on associations between neoplasms and neuromyelitis optica spectrum disorder (NMOSD) have been published over the past decade. However, types of neoplasms and temporal relationships have not been widely studied.
Objective: To report cases and determine the associations between neoplasms and NMOSD.
Method: A retrospective chart review of possible paraneoplastic NMOSD patients at a university hospital was performed. Articles related to "neoplasm" and "NMOSD" were systematically searched and reviewed. We included aquaporin-4 (AQP4)-IgG-seropositive NMOSD patients whose onset of NMOSD and cancer diagnosis or recurrence were within 24 months of one another. Temporal relationship, types of neoplasms involved, treatments, and outcomes of both NMOSD and neoplasms were determined. The subgroup analysis was based on the AQP4 expression of neoplasm histology.
Results: We identified 3 cases (1.3%) from a cohort of 224 AQP4-IgG-seropositive NMOSD at our hospital and retrieved 68 cases from a systematic review, totaling 71 cases of possible paraneoplastic NMOSD. The median age at onset of NMOSD was 55 (IQR 41-64) years. Eighty percent were female. The most frequently identified types of neoplasms were lung and breast, accounting for 21.1% and 18.3%, respectively. The other tumor types were ovarian tumors and hematologic malignancy, both at 12.7%. The most commonly identified tissue histology was adenocarcinoma (52.1%). We also reported the first case of melanoma in an NMOSD patient. Twenty-eight patients (39.4%) were diagnosed with cancer before the onset of NMOSD with a median duration of 9.5 (range 1-24) months. Of those, eight patients had NMOSD after surgical removal of neoplasms, and one patient had NMOSD after radiotherapy of prostate adenocarcinoma. Twenty-three patients (32.4%) had NMOSD before cancer diagnosis by a median of 3 (range 1-24) months, and the rest were diagnosed concurrently during the same admission. Three cases were diagnosed with NMOSD around the time of tumor recurrence. Tumor tissue expressed AQP4 in 82.4%.
Conclusion: A small proportion of AQP4-IgG-positive NMOSD is associated with malignancy. In newly diagnosed NMOSD patients without symptoms of neoplasms, screening for age- and risk-appropriate cancer should be recommended, similar to the general population. The occurrence of NMOSD in cancer patients might suggest tumor recurrence.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2022.104212 | DOI Listing |
Mult Scler
September 2025
Department of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA.
Background: Financial toxicity (FT) and the social determinants of health (SDOH) remain underexplored in neuromyelitis optica spectrum disorder (NMOSD).
Objective: To characterize FT in NMOSD and examine sociodemographic and clinical features.
Methods: We conducted a convenience-sampled, cross-sectional, anonymous survey (08/2024-03/2025) of 124 U.
Clin Neurol Neurosurg
October 2025
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Gorlin Goltz syndrome is an autosomal dominant multisystem disorder characterized, among other features, by multiple early-onset basal cell carcinomas (BCCs). After receiving Cemiplimab, she developed aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Objective: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions.
View Article and Find Full Text PDFBMJ Neurol Open
August 2025
Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, Abu Dhabi, UAE.
Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system (CNS). Management during pregnancy is challenging due to limited safety data for disease-modifying therapies. We report a case of a 41-year-old woman with aquaporin-4 (AQP4) IgG positive NMOSD who was switched from rituximab to ravulizumab during pregnancy.
View Article and Find Full Text PDFCureus
August 2025
Neurology, Palmetto General Hospital, Miami, USA.
Transverse myelitis (TM) is an inflammatory disorder of the spinal cord often associated with autoimmune diseases, such as systemic lupus erythematosus (SLE) or neuromyelitis optica spectrum disorder (NMOSD); however, it is rarely linked to rheumatoid arthritis (RA). We present the case of a 28-year-old woman with subacute ascending numbness, lancinating pain, and bilateral lower extremity weakness resulting in significant functional impairment. Despite upper motor neuron signs on examination and supportive cerebrospinal fluid findings, including elevated gamma globulins and positive myelin basic protein, spinal MRI remained negative.
View Article and Find Full Text PDF